Literature DB >> 19301059

Recent in vitro findings of negative inotropy of pantoprazole did not translate into clinically relevant effects on left ventricular function in healthy volunteers.

Wolfgang Schillinger1, Nina Hörnes, Nils Teucher, Samuel Sossalla, Daniel Sehrt, Klaus Jung, Mark Hünlich, Bernhard Unsöld, Bianca Geiling, Giuliano Ramadori, Reinhard Hilgers, Harald Schwörer, Gerd Hasenfuss.   

Abstract

PURPOSE: Reports on cardiac problems with oral proton pump inhibitors have caused extensive safety reviews by the US Food and Drug Administration. We provide additional data on acute cardiac effects of an intravenous application.
METHODS: Echocardiography was performed in 18 healthy volunteers after administration of a common high-dose regimen of pantoprazole (80 mg i.v. bolus followed by 8 mg/h for 1 h) or placebo.
DESIGN: The design included a randomized, double-blind, placebo-controlled cross-over trial.
RESULTS: Ejection fraction (%, mean +/- SE) in the treatment group (placebo group) was 60.7 +/- 1.1 (61.2 +/- 1.7) at baseline, and 62.6 +/- 1.1 (62.1 +/- 1.9), 64.7 +/- 1.6 (63.5 +/- 1.3), 62.6 +/- 1.6 (61.0 +/- 1.6) and 63.0 +/- 1.4 (61.8 +/- 1.5) at 7.5, 15, 30 and 60 min after bolus application, respectively (p = n.s.). Similarly, no significant changes were found for cardiac output, cardiac index, blood pressure and heart rate. In contrast, gastric pH that was used as a treatment control was significantly increased 60 min after the application of pantoprazole as compared to baseline and to placebo.
CONCLUSIONS: Pantoprazole as injection is safe in healthy subjects with respect to cardiac contractile function. However, in view of recent reports of negative inotropy of the drug, further studies in heart failure patients are required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301059      PMCID: PMC2698968          DOI: 10.1007/s00392-009-0012-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  27 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

2.  Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? AT1-receptor antagonists?

Authors:  Uta C Hoppe
Journal:  Clin Res Cardiol       Date:  2007-02-15       Impact factor: 5.460

3.  Pheochromocytoma, a rare cause of acute cardiogenic shock.

Authors:  Ole Eschen; Ole Frøbert; Vibeke Jensen; Steen Hvitfeldt Poulsen
Journal:  Clin Res Cardiol       Date:  2007-03-21       Impact factor: 5.460

4.  Takotsubo cardiomyopathy with an unusual pattern of regional left ventricular wall motion abnormalities.

Authors:  Claudia Dellas; Gerd Hasenfuss; Dirk Vollmann
Journal:  Clin Res Cardiol       Date:  2007-04-26       Impact factor: 5.460

Review 5.  Proton pump inhibitors: an update of their clinical use and pharmacokinetics.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-08-05       Impact factor: 2.953

Review 6.  Functional consequences of sarcomeric protein abnormalities in failing myocardium.

Authors:  Martin M LeWinter
Journal:  Heart Fail Rev       Date:  2005-09       Impact factor: 4.214

7.  Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions.

Authors:  Gilaad G Kaplan; Duane Bates; Dawn McDonald; Remo Panaccione; Joseph Romagnuolo
Journal:  Clin Gastroenterol Hepatol       Date:  2005-12       Impact factor: 11.382

8.  N-terminal B-type natriuretic peptide concentrations are similarly increased by 30 minutes of moderate and brisk walking in patients with coronary artery disease.

Authors:  Jürgen Scharhag; Markus Herrmann; Melanie Weissinger; Wolfgang Herrmann; Wilfried Kindermann
Journal:  Clin Res Cardiol       Date:  2007-02-26       Impact factor: 5.460

9.  Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms.

Authors:  Wolfgang Schillinger; Nils Teucher; Samuel Sossalla; Sarah Kettlewell; Carola Werner; Dirk Raddatz; Andreas Elgner; Gero Tenderich; Burkert Pieske; Giuliano Ramadori; Friedrich A Schöndube; Harald Kögler; Jens Kockskämper; Lars S Maier; Harald Schwörer; Godfrey L Smith; Gerd Hasenfuss
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

10.  Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists?

Authors:  Iwan C C van der Horst; Adriaan A Voors; Dirk J van Veldhuisen
Journal:  Clin Res Cardiol       Date:  2007-02-15       Impact factor: 5.460

View more
  5 in total

1.  Echocardiogram study to evaluate the effect of the novel hepatitis C virus NS5A inhibitor GSK2336805 on cardiac contractility in healthy subjects.

Authors:  D A Wilfret; K K Adkison; L A Jones; Y Lou; J Gan; W Spreen
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

2.  Hotlines and clinical trial updates presented at the European Society of Cardiology Meeting 2009: data from RE-LY, PLATO, MADIT-CRT, PROTECT, SYNTAX, TRITON and more.

Authors:  S H Schirmer; A M van der Laan; M Böhm; F Mahfoud
Journal:  Clin Res Cardiol       Date:  2009-11       Impact factor: 5.460

3.  A comparative evaluation of electrical velocimetry and inert gas rebreathing for the non-invasive assessment of cardiac output.

Authors:  Frederik Trinkmann; Manuel Berger; Ursula Hoffmann; Martin Borggrefe; Jens J Kaden; Joachim Saur
Journal:  Clin Res Cardiol       Date:  2011-07-01       Impact factor: 5.460

4.  Proton pump inhibitors and the risk of adverse cardiac events.

Authors:  David N Juurlink; Colin R Dormuth; Anjie Huang; Chelsea Hellings; J Michael Paterson; Colette Raymond; Anita Kozyrskyj; Yola Moride; Erin M Macdonald; Muhammad M Mamdani
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

5.  Use of Proton-Pump Inhibitors Predicts Heart Failure and Death in Patients with Coronary Artery Disease.

Authors:  Ana María Pello Lázaro; Carmen Cristóbal; Juan Antonio Franco-Peláez; Nieves Tarín; Álvaro Aceña; Rocío Carda; Ana Huelmos; María Luisa Martín-Mariscal; Jesús Fuentes-Antras; Juan Martínez-Millá; Joaquín Alonso; Óscar Lorenzo; Jesús Egido; Lorenzo López-Bescós; José Tuñón
Journal:  PLoS One       Date:  2017-01-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.